
Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.
Johnson & Johnson continues to show resilience with a 64-year dividend increase streak and raised full-year revenue and earnings guidance for 2026. Despite its strong business fundamentals and leadership in pharmaceuticals and medical devices, the st...





